Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Do antiretrovirals reduce the risk of non-AIDS-defining malignancies?

Silverberg MJ, Abrams DI.

Curr Opin HIV AIDS. 2009 Jan;4(1):42-51. doi: 10.1097/COH.0b013e32831a9875.

2.

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, Hidalgo J, Lourtau L, Neaton JD, Tambussi G, Abrams DI.

AIDS. 2007 Sep 12;21(14):1957-63.

PMID:
17721103
3.

Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy.

Galli L, Spagnuolo V, Poli A, Salpietro S, Gianotti N, Cossarini F, Carbone A, Nozza S, Bossolasco S, Bigoloni A, Lazzarin A, Castagna A.

AIDS. 2014 Oct 23;28(16):2407-15. doi: 10.1097/QAD.0000000000000443.

PMID:
25160933
4.

AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era.

Silverberg MJ, Abrams DI.

Curr Opin Oncol. 2007 Sep;19(5):446-51. Review.

PMID:
17762569
5.

Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort.

Hleyhel M, Hleyhel M, Bouvier AM, Belot A, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL, Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, Costagliola D, Grabar S; Cancer Risk Group of the French Hospital Database on HIV (FHDH-ANRS CO4).

AIDS. 2014 Sep 10;28(14):2109-18. doi: 10.1097/QAD.0000000000000382.

PMID:
25265077
6.

Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development.

Chiu CG, Smith D, Salters KA, Zhang W, Kanters S, Milan D, Montaner JSG, Coldman A, Hogg RS, Wiseman SM.

BMC Cancer. 2017 Apr 14;17(1):270. doi: 10.1186/s12885-017-3229-1.

7.

Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.

Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D; Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort.

Lancet Oncol. 2009 Dec;10(12):1152-9. doi: 10.1016/S1470-2045(09)70282-7. Epub 2009 Oct 7.

PMID:
19818686
8.

Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk.

Borges AH, Dubrow R, Silverberg MJ.

Curr Opin HIV AIDS. 2014 Jan;9(1):34-40. doi: 10.1097/COH.0000000000000025. Review.

9.

Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study.

Dauby N, De Wit S, Delforge M, Necsoi VC, Clumeck N.

J Int AIDS Soc. 2011 Mar 28;14:16. doi: 10.1186/1758-2652-14-16.

10.

HIV infection and the risk of cancers with and without a known infectious cause.

Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, Klein D, Quesenberry CP Jr, Towner WJ, Abrams DI.

AIDS. 2009 Nov 13;23(17):2337-45. doi: 10.1097/QAD.0b013e3283319184.

11.

Evolving epidemiology of malignancies in HIV.

Bonnet F, Chêne G.

Curr Opin Oncol. 2008 Sep;20(5):534-40. doi: 10.1097/CCO.0b013e32830a5080. Review.

PMID:
19106656
12.

The growing problem of non-AIDS-defining malignancies in HIV.

Pantanowitz L, Schlecht HP, Dezube BJ.

Curr Opin Oncol. 2006 Sep;18(5):469-78. Review.

PMID:
16894295
13.

[HIV-related malignancies: state of art].

Gobert A, Mounier N, Lavole A, Poizot-Martin I, Spano JP.

Bull Cancer. 2014 Nov;101(11):1020-9. doi: 10.1684/bdc.2014.2032. Review. French.

PMID:
25418594
14.

Cancer in the HIV-Infected Host: Epidemiology and Pathogenesis in the Antiretroviral Era.

Brickman C, Palefsky JM.

Curr HIV/AIDS Rep. 2015 Dec;12(4):388-96. doi: 10.1007/s11904-015-0283-7. Review.

PMID:
26475669
15.

Non-AIDS-defining cancers and HIV infection.

Lim ST, Levine AM.

Curr HIV/AIDS Rep. 2005 Aug;2(3):146-53. Review.

PMID:
16091262
16.

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.

Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S; Swiss HIV Cohort.

J Natl Cancer Inst. 2005 Mar 16;97(6):425-32.

PMID:
15770006
17.

Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression.

Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):203-8. doi: 10.1097/QAI.0b013e3181b033ab.

18.

HIV infection and cancer in the era of highly active antiretroviral therapy (Review).

Barbaro G, Barbarini G.

Oncol Rep. 2007 May;17(5):1121-6. Review.

PMID:
17390054
19.

Screening for HIV: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation.

Chou R, Selph S, Dana T, Bougatsos C, Zakher B, Blazina I, Korthuis PT.

Ann Intern Med. 2012 Nov 20;157(10):706-18. doi: 10.7326/0003-4819-157-10-201211200-00007. Review.

PMID:
23165662
20.

Cancer burden in the HIV-infected population in the United States.

Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA.

J Natl Cancer Inst. 2011 May 4;103(9):753-62. doi: 10.1093/jnci/djr076. Epub 2011 Apr 11.

Supplemental Content

Support Center